Hims & Hers swung to a loss as it pivoted away from cheaper weight loss drugs

The telehealth company posted a net loss of $92 million in the first quarter as its shift away from compounded weight loss drugs drove up costs

Cheng Xin / Getty Images

Hims & Hers swung to a net loss of $92.1 million in the first quarter of 2026, compared with net income of $49.5 million in the same period a year earlier, as the company pivoted away from cheaper compounded weight loss drugs toward branded GLP-1 medications.

Revenue rose 4% year over year to $608.1 million, the company said. Gross margin fell to 65% from 73% in the prior-year period, and adjusted EBITDA dropped to $44.3 million........

© Quartz